Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
13 October 2010 - 3:17AM
Marketwired
Tecan Group AG /
Tecan Group and Luminex Corporation Partner to Develop Automated
Newborn Screening Solution
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this
announcement.
New solution combines multiplexing and automation technologies
to create novel system that provides faster results and saves
valuable time and resources in newborn screening laboratories
Männedorf, Switzerland, and Austin, Texas - October 12, 2010 -
The Tecan Group (SWISS: TECN) and Luminex Corporation (NASDAQ:
LMNX) have announced that they will collaborate on the development
of a new automated newborn screening solution that will provide
faster results for infants' potential health concerns. The
companies have entered into a global OEM agreement that allows them
to combine Luminex® xMAP® technology and LX 200™ instrument with
Tecan's flexible and reliable Freedom EVO® liquid handling platform
and HydroFlex™ washer. The new automated newborn screening solution
will help laboratories enhance efficiency, save vital resources and
analyze more samples more quickly. Luminex expects to launch the
automated newborn screening solution in 2011.
Thomas Bachmann, CEO of Tecan, said: "We are delighted that we
have been chosen by Luminex to supply a fully automated solution
for such an important application. This global OEM agreement is
building on a long, well established partnership of creating the
most advanced automated solutions in the research market for
Luminex xMAP technology."
Luminex xMAP technology enables large numbers of biological
tests to be conducted simultaneously and analyzed quickly,
cost-effectively and accurately. Once it receives regulatory
clearance, NeoPlex4™ will be a fully automated, walk-away testing
platform for multiplexed newborn screening. These high-volume
screening assays test newborn infants for several different
biomarkers linked to critical diseases. Each of these conditions
can cause severe mental and physical disability if untreated. If
detected early through testing, effective treatment can be
initiated. Multiplexing these tests together from one sample offers
significant improvements in testing efficiency.
Patrick Balthrop, CEO of Luminex, said: "Automation continues to
be a top priority for Luminex and our customers. The high testing
volumes in the newborn screening market require full
sample-to-answer automation for the thousands of specimens
processed by each customer per day. We evaluated several different
robotic solutions to achieve this full automation for our xMAP
technology and determined that Tecan was the best option available
for this application. We have had a very effective relationship
with Tecan and we are proud to be partnered with them in this
effort."
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics, and
clinical diagnostics. The company specializes in the development,
production and distribution of instruments and automated workflow
solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university
research departments, forensic and diagnostic laboratories. As an
original equipment manufacturer, Tecan is also a leader in
developing and manufacturing OEM instruments and components that
are then distributed by partner companies. Founded in Switzerland
in 1980, the company has manufacturing, research and development
sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2009, Tecan generated sales of
CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered
shares of Tecan Group are traded on the SIX Swiss Exchange (TK:
TECN/Reuters: TECZn.S/ ISIN CH0012100191).
About Luminex Corporation
Luminex Corporation develops, manufactures and markets
proprietary biological testing technologies with applications
throughout the diagnostic and life sciences industries. The
Company's xMAP® multiplex solutions include an open- architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics markets. The
Company's xMAP Technology is sold worldwide and is already in use
in leading clinical laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on
Luminex Corporation or xMAP Technology can be obtained at
www.luminexcorp.com.
For further information:
Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Luminex Contacts:
Luminex Corporate Contact:
Harriss T. Currie
Vice President, Finance and Chief Financial Officer
512.219.8020
hcurrie@luminexcorp.com
Matthew Scalo
Sr. Director Investor Relations
512.219.8020
mscalo@luminexcorp.com
Luminex Media Contact:
Aaron DeLucia
512.241.2249
aaron.delucia@porternovelli.com
[HUG#1450913]
--- End of Message ---
Tecan Group AG Seestrasse 103 Männedorf Switzerland
ISIN: CH0012100191;
Press Release (PDF):
http://hugin.info/100384/R/1450913/392318.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024